Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Mark Jeffrey Delong Sells 363 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) insider Mark Jeffrey Delong sold 363 shares of the company’s stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $28.54, for a total value of $10,360.02. Following the completion of the sale, the insider now owns 83,945 shares of the company’s stock, valued at approximately $2,395,790.30. The trade was a 0.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Apellis Pharmaceuticals Price Performance

Shares of Apellis Pharmaceuticals stock opened at $28.51 on Thursday. The stock has a 50 day moving average of $31.45 and a 200 day moving average of $32.30. Apellis Pharmaceuticals, Inc. has a 12 month low of $24.34 and a 12 month high of $71.90. The firm has a market cap of $3.55 billion, a PE ratio of -14.04 and a beta of 0.96. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Analysts Set New Price Targets

A number of analysts have commented on APLS shares. Needham & Company LLC reduced their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Wells Fargo & Company reduced their price target on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Robert W. Baird dropped their price objective on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Mizuho dropped their price objective on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Finally, Bank of America dropped their price objective on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Apellis Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Apellis Pharmaceuticals by 2.3% during the fourth quarter. Vanguard Group Inc. now owns 10,046,025 shares of the company’s stock valued at $320,569,000 after buying an additional 230,450 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Apellis Pharmaceuticals by 23.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock valued at $112,036,000 after purchasing an additional 735,160 shares during the last quarter. Braidwell LP lifted its stake in shares of Apellis Pharmaceuticals by 410.8% in the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock valued at $90,130,000 after purchasing an additional 2,513,383 shares during the last quarter. Jennison Associates LLC lifted its stake in shares of Apellis Pharmaceuticals by 51.6% in the 4th quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock valued at $88,084,000 after purchasing an additional 939,289 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after purchasing an additional 1,409,707 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).